Intraperitoneal Mitomycin C for Abdominal Cancer
Author Information
Author(s): SS Ubhil, P McCulloch, PS Veitch
Primary Institution: Leicester Royal Infirmary NHS Trust
Hypothesis
Is intraperitoneal mitomycin C safe and effective for treating intra-abdominal malignancies?
Conclusion
The study found that intraperitoneal mitomycin C is not safe in the presence of anastomosis or suture lines, leading to severe complications.
Supporting Evidence
- Four out of seven patients who underwent gastric resection developed fatal complications.
- Complications included multiple organ failure and coeliac axis rupture, which are unusual for gastrectomy.
- The treatment was associated with a high incidence of severe complications compared to previous studies.
Takeaway
Doctors tried a new treatment for stomach cancer using a special medicine, but it made some patients very sick and even caused deaths.
Methodology
Patients received various doses of mitomycin C adsorbed onto activated carbon particles during surgery.
Potential Biases
The older age of British patients compared to Japanese patients may have influenced the results.
Limitations
The study had a small sample size and was not a formal phase I study with dose escalation.
Participant Demographics
Eleven patients, mostly older males with gastric adenocarcinoma and pseudomyxoma.
Want to read the original?
Access the complete publication on the publisher's website